David McCall, Senior Editor, Cell & Gene Therapy Insights, speaks to Shashwati Basak, Vice President, Cell and Gene Therapy, Intas Pharmaceuticals, about the availability of autologous CAR-T cell therapies in India, the current state of regulatory guidance in the country, and the phase-appropriate analytical control of cell therapy manufacture. As engineered cell therapy products rapidly increase in complexity, it is critical that costs are reduced to ensure affordability to patients worldwide, including those in India.
